What the FDA labels say about taking them together
Rosuvastatin and sofosbuvir/velpatasvir/voxilaprevir
Rosuvastatin's FDA label of September 4, 2026 names sofosbuvir/velpatasvir/voxilaprevir in its drug interactions section, and sofosbuvir/velpatasvir/voxilaprevir's label names rosuvastatin too. The sofosbuvir/velpatasvir/voxilaprevir label: “Coadministration of VOSEVI with rosuvastatin may significantly increase the concentration of rosuvastatin which is associated with increased risk of myopathy, including rhabdomyolysis. …”
Check it at the source: the rosuvastatin FDA label on DailyMed (effective September 4, 2026, ScieGen Pharmaceuticals, Inc.); the sofosbuvir/velpatasvir/voxilaprevir FDA label on DailyMed (effective July 14, 2025, Gilead Sciences, Inc.).
What does the rosuvastatin label say about sofosbuvir/velpatasvir/voxilaprevir?
Rosuvastatin label, drug interactionsDrug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with Rosuvastatin Tablets Sofosbuvir/velpatasvir/voxilaprevir or Ledipasvir/sofosbuvir Prevention or Management:
Source: FDA drug label (Crestor, NDA021366), AstraZeneca Pharmaceuticals LP, effective April 29, 2026 (SPL set 325a5d0e-9a72-4015-9fcd-1655fb504cee), via openFDA
Source: FDA drug label (Rosuvastatin), ScieGen Pharmaceuticals, Inc., effective September 4, 2026 (SPL set ee4933c5-0d97-494d-ac0f-2083e0100836), via openFDA; the full label on DailyMed
What does the sofosbuvir/velpatasvir/voxilaprevir label say about rosuvastatin?
Sofosbuvir/velpatasvir/voxilaprevir label, drug interactionsConcomitant Drug Class/Drug Name: rosuvastatin; Effect on Concentration ↓ = decrease, ↑ = increase.: ↑ rosuvastatin; Clinical Effect/Recommendation: Coadministration of VOSEVI with rosuvastatin may significantly increase the concentration of rosuvastatin which is associated with increased risk of myopathy, including rhabdomyolysis. Coadministration of VOSEVI with rosuvastatin is not recommended.
Source: FDA drug label (Vosevi), Gilead Sciences, Inc., effective July 14, 2025 (SPL set 17ffc094-8ca7-45d2-80d8-fd043bc9a221), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Rosuvastatin | Sofosbuvir/velpatasvir/voxilaprevir | |
|---|---|---|
| Labeled for | Heart attack and coronary artery disease, High cholesterol, High triglycerides, Stroke prevention | Hepatitis C |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.0692 per tablet 40 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once